Friday - april 11
| 09.00 - 11.50 | SCIENTIFIC SESSION III | |
| Chairs: J.-M. KAUFMAN & S. ATIK | ||
| 09.00 - 09.30 | Plenary lecture | |
| Future management of osteoporosis: clinical and economic challenges | ||
| J. COMPSTON | ||
| 09.30 - 10.00 | Oral Communications selected from abstracts | |
09:30–09:40 OC26 |
TIMING OF FIRST INFUSION OF ZOLEDRONIC ACID 5 MG AFTER RECENT HIP FRACTURE AFFECTS ANTIFRACTURE EFFICACY AND REDUCTION OF MORTALITY E.F. Eriksen, K.W. Lyles, C.S. Colon-Emeric, C.F. Pieper, J.S. Magaziner, J.D. Adachi, L. Hyldstrup, L. Nordsletten, S. Boonen, P. Mesenbrink |
|
09:40–09:50 OC27 |
STRONTIUM RANELATE DEMONSTRATES EFFICACY OVER 3 AND 4 YEARS AGAINST VERTEBRAL FRACTURE IN YOUNG POSTMENOPAUSAL WOMEN (50-65 YEARS) WITH SEVERE OSTEOPOROSIS |
|
09:50–10:00 OC28
|
A MARKOV MODEL OF ECONOMIC IMPACT OF PERSISTENCE IMPROVEMENT WITH BISPHOSPHONATE TREATMENT AMONG FRENCH WOMEN DIAGNOSED FOR POSTMENOPAUSAL OSTEOPOROSIS |
|
| 10.00 - 10.30 | Plenary lecture | |
| Future management of osteoarthritis: clinical and economic targets | ||
| F. GUILLEMIN | ||
| 10.30 - 11.50 | Oral Communications selected from abstracts | |
10:30–10:40 OC29 |
LONG TERM STUDY OF THREE DOSAGES OF EPICUTANEOUSLY APPLIED DIRACTIN® (KETOPROFEN IN TRANSFERSOME®) IN PATIENTS WITH OSTEOARTHRITIS (OA) OF THE KNEE G. Stucki, M. Rother |
|
10:40–10:50 OC30 |
KNEE OSTEOARTHRITIS SYNOVIAL MEMBRANE THICKNESS: PRECISE AND RELIABLE ASSESSMENT BY MRI |
|
10:50–11:00 OC31 |
BISPHOSPHONATE THERAPY AND HIP FRACTURES WITHIN THE RISEDRONATE AND ALENDRONATE (REAL) COHORT STUDY: SUBGROUP WITH PRIOR FRACTURE P.D. Delmas, S.L. Silverman, N.B. Watts, J.L. Lange, R. Lindsay |
|
11:00–11:10 OC32 |
VITAMIN-D 800 IU/day + CALCIUM 1000 mg SUPPLEMENTATION DECREASES THE RISK OF RECURRENT FALLING AMONG POSTMENOPAUSAL AMBULATORY WOMEN - A POPULATION-BASED, RANDOMIZED, 3-YEAR STUDY (OSTPRE-FPS) M. Kärkkäinen, M. Tuppurainen, T. Rikkonen, K. Salovaara, J. Sirola, R. Honkanen, J. Arokoski, E. Alhava, H. Kröger |
|
11:10–11:20 OC33 |
BISPHOSPHONATE EFFICACY ON FRACTURE RISK IN WOMEN SELECTED BY 10-YEAR FRACTURE PROBABILITY |
|
11:20–11:30 OC34 |
CHANGES IN FEMORAL NECK BONE MINERAL DENSITY ARE ASSOCIATED WITH HIP FRACTURE INCIDENCE IN UNTREATED POSTMENOPAUSAL WOMEN |
|
11:30–11:40 OC35 |
EFFECTS OF ANTI-SCLEROSTIN MONOCLONAL ANTIBODY IN HEALTHY |
|
11:40–11:50 OC36 |
EVALUATION OF DENOSUMAB IN A 48-MONTH RANDOMIZED, BLINDED, PHASE 2 TRIAL |
|
| 12.15 - 13.45 | New Strategies for Postmenopausal Care | Recent developments in targeting RANK Ligand in osteoporosis |
| Lunch Symposium sponsored by ELI LILLY | Lunch Symposium sponsored by AMGEN | |
| Co-chairs: D. AGNUSDEI, P.D. DELMAS | Chairman: J.-Y. REGINSTER | |
| Role of bone quality in the pathophysiology of vertebral and nonvertebral fractures |
Cortical bone – the impact of non-vertebral fractures | |
| E. SEEMAN | J. KANIS | |
| SERMS - An innovative option to prevent fractures and invasive breast cancer in postmenopausal women | The effect of RANK Ligand inhibition on cortical and trabecular bone strength in primates |
|
| P.D. DELMAS | T. THOMAS | |
| Teriparatide treatment in patients with glucocorticoid-induced osteoporosis | Four years experience with RANK Ligand inhibition in postmenopausal patients with low bone mass |
|
| H. DOBNIG | H. RESCH | |
| 13.45 - 15.00 | Poster Session & Exhibition Viewing Posters P225 to P349 will be manned |
|
| 14.00 - 15.00 | Meet-The-Professor Session | |
| Who will benefit from calcium/vitamin D supplementation - B. DAWSON-HUGHES How to monitor anti-osteoporosis treatment ? - R. RIZZOLI Management of glucocorticoid-induced osteoporosis - S. PAPAPOULOS Role of the orthopaedic surgeon in the management of osteoporosis - T. EINHORN |
||
| 15.00 - 16.40 | SCIENTIFIC SESSION IV | |
| Chairs: J. KANIS & S. PAPAPOULOS | ||
| 15.00 - 15.30 | Plenary lecture | |
| Bone quality: myth or reality? | ||
| R. RIZZOLI | ||
| 15.30 - 16.40 | Oral Communications selected from abstracts | |
15:30–15:40 OC37 |
RISK OF FRACTURE IN POSTMENOPAUSAL WOMEN TAKING CONCOMITANT BISPHOSPHONATE AND ACID-SUPPRESSANT MEDICATION |
|
15:40–15:50 OC38 |
NAPROXCINOD COMPARED TO NAPROXEN AND PLACEBO IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE: RESULTS OF A 13-WEEK RANDOMIZED, CONTROLLED TRIAL |
|
15:50–16:00 OC39 |
RESPONSIVENESS TO TERIPARATIDE IS GREATER IN PATIENTS PREVIOUSLY TREATED WITH RISEDRONATE THAN IN THOSE PREVIOUSLY TREATED WITH ALENDRONATE: THE OPTAMISE STUDY |
|
16:00–16:10 OC40 |
EFFICACY OF BAZEDOXIFENE IN REDUCING NEW VERTEBRAL FRACTURE RISK IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM A 3-YEAR, RANDOMIZED, PLACEBO- AND ACTIVE- CONTROLLED CLINICAL TRIAL |
|
16:10–16:20 OC41 |
SOME BUT NOT ALL ESTROGEN-LIKE MOLECULES HAVE BOTH BONE AND CARTILAGE PROTECTIVE EFFECTS – EVIDENCE FOR COMPLETE UNCOUPLING OF BONE AND CARTILAGE EFFECTS |
|
16:20–16:30 OC42 |
RISK FACTORS FOR HIP FRACTURE IN MEN |
|
16:30–16:40 OC43 |
A SINGLE INFUSION OF ZOLEDRONIC ACID 5 MG (ZOL) IS SIGNIFICANTLY MORE EFFECTIVE THAN DAILY ORAL RISEDRONATE 5 MG (RIS) IN INCREASING BONE MINERAL DENSITY (BMD) OF THE LUMBAR SPINE (LS), HIP, FEMORAL NECK AND TROCHANTER IN PATIENTS WITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS (GIO) D.M. Reid, J.-P. Devogelaer, K. Saag, C. Roux, C.S. Lau, J.-Y. Reginster, P. Papanastasiou, A. Ferreira, T. Fashola, P. Sambrook |
|
| 17.00 - 18.30 | Strengthening osteoporosis management: an evidence-based review |
Glucosamine sulfate as an option among pharmacological treatments of osteoarthritis in the contest of current practice guideline |
| Satellite Symposium sponsored by ROCHE & GLAXOSMITHKLINE |
Satellite Symposium sponsored by ROTTAPHARM MADAUS | |
| Chair: P.D. DELMAS | Chairman: S. ATIK | |
| Welcome and introduction | An overiew of current practice guideline for the pharmacological treatment of osteoarthritis |
|
| P.D. DELMAS | W. ZHANG | |
| Bone strength assessment: from DXA to micro imaging | Are all glucosamine formulations the same? Pharmacokinetics and pharmacodynamics considerations | |
| M. BOUXSEIN | R. ALTMAN | |
| An assessment of ibandronate data from pivotal trials | An evidence-based assessment of the efficacy and safety of glucosamine sulfate in osteoarthritis |
|
| A. KURTH | L. ROVATI | |
| Reducing non-vertebral fracture risk: ibandronate doses used in clinical practice | ||
| J.-Y. REGINSTER | ||
| New evidence: a comparison of oral bisphosphonates | ||
| P.D. DELMAS | ||
| Summary | ||
| P.D. DELMAS | ||